Biotech IV Monitor

RARE — Ultragenyx Pharmaceutical Inc.

$2.6B market cap · 7 upcoming readouts tracked

Clinical trial readout dates for Ultragenyx Pharmaceutical Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.

Next readoutJanuary 2027in ~2 months
Upcoming readouts75 Phase 3
Market cap$2.6B
Cash & investments$467M~4 quarters at last loss rate
Recent 8-K filings1latest 2026-11-03

Upcoming readouts

Phase 3 setrusumab
Osteogenesis Imperfecta · NCT06636071
January 2027
Ongoing
Phase 3 No Investigational Product
Mucopolysaccharidosis IIIA; MPS IIIA · NCT04360265
August 2027
Enrolling
Phase 3 Triheptanoin
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) · NCT05933200
August 2027
Ongoing
Phase 3 DTX301
OTC Deficiency · NCT05345171
September 2027
Ongoing
Phase 1/2 UX016
GNE Myopathy · NCT07511556
December 2028
Recruiting
Phase 2/3 UX111
MPS IIIA; Sanfilippo Syndrome · NCT02716246
March 2029
Recruiting
Phase 1/2 UX701
Wilson Disease · NCT04884815
March 2029
Ongoing

Cash position

Ultragenyx Pharmaceutical Inc. reported $467M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $118M; at that rate the cash would last about 4 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-03

Companies working on similar indications

Discussion

No messages yet. If you follow RARE, you can start the conversation.
Track RARE in real time
See live implied volatility for RARE and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on RARE
Contact — questions or corrections about RARE: dukeupt@gmail.com